Quercetin abrogates chemoresistance in melanoma cells by modulating ΔNp73

Thilakavathy Thangasamy, Sivanandane Sittadjody, Geoffrey C. Mitchell, Erin E. Mendoza, Vijayababu M. Radhakrishnan, Kirsten Limesand, Randy M Burd

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: The alkylating agent Dacarbazine (DTIC) has been used in the treatment of melanoma for decades, but when used as a monotherapy for cancer only moderate response rates are achieved. Recently, the clinical use of Temozolomide (TMZ) has become the more commonly used analog of DTIC-related oral agents because of its greater bioavailability and ability to cross the blood brain barrier. The response rates achieved by TMZ are also unsatisfactory, so there is great interest in identifying compounds that could be used in combination therapy. We have previously demonstrated that the bioflavonoid quercetin (Qct) promoted a p53-mediated response and sensitized melanoma to DTIC. Here we demonstrate that Qct also sensitizes cells to TMZ and propose a mechanism that involves the modulation of a truncated p53 family member, ΔNp73.Methods: DB-1 melanoma (p53 wildtype), and SK Mel 28 (p53 mutant) cell lines were treated with TMZ (400 μM) for 48 hrs followed by Qct (75 μM) for 24 hrs. Cell death was determined by Annexin V-FITC staining and immunocytochemical analysis was carried out to determine protein translocation.Results: After treatment with TMZ, DB-1 cells demonstrated increased phosphorylation of Ataxia telangiectasia mutated (ATM) and p53. However, the cells were resistant to TMZ-induced apoptosis and the resistance was associated with an increase in nuclear localization of ΔNp73. Qct treatment in combination with TMZ abolished drug insensitivity and caused a more than additive induction of apoptosis compared to either treatment alone. Treatment with Qct, caused redistribution of ΔNp73 into the cytoplasm and nucleus, which has been associated with increased p53 transcriptional activity. Knockdown of ΔNp73 restored PARP cleavage in the TMZ treated cells, confirming its anti-apoptotic role. The response to treatment was predominantly p53 mediated as the p53 mutant SK Mel 28 cells showed no significant enhancement of apoptosis.Conclusion: This study demonstrates that Qct can sensitize cells to TMZ and that the mechanisms of sensitization involve modulation of p53 family members.

Original languageEnglish (US)
Article number282
JournalBMC Cancer
Volume10
DOIs
StatePublished - Jun 11 2010

Fingerprint

temozolomide
Quercetin
Melanoma
Dacarbazine
Apoptosis
Ataxia Telangiectasia
Aptitude
Fluorescein-5-isothiocyanate
Annexin A5
Alkylating Agents
Protein Transport

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics

Cite this

Thangasamy, T., Sittadjody, S., Mitchell, G. C., Mendoza, E. E., Radhakrishnan, V. M., Limesand, K., & Burd, R. M. (2010). Quercetin abrogates chemoresistance in melanoma cells by modulating ΔNp73. BMC Cancer, 10, [282]. https://doi.org/10.1186/1471-2407-10-282

Quercetin abrogates chemoresistance in melanoma cells by modulating ΔNp73. / Thangasamy, Thilakavathy; Sittadjody, Sivanandane; Mitchell, Geoffrey C.; Mendoza, Erin E.; Radhakrishnan, Vijayababu M.; Limesand, Kirsten; Burd, Randy M.

In: BMC Cancer, Vol. 10, 282, 11.06.2010.

Research output: Contribution to journalArticle

Thangasamy, T, Sittadjody, S, Mitchell, GC, Mendoza, EE, Radhakrishnan, VM, Limesand, K & Burd, RM 2010, 'Quercetin abrogates chemoresistance in melanoma cells by modulating ΔNp73', BMC Cancer, vol. 10, 282. https://doi.org/10.1186/1471-2407-10-282
Thangasamy T, Sittadjody S, Mitchell GC, Mendoza EE, Radhakrishnan VM, Limesand K et al. Quercetin abrogates chemoresistance in melanoma cells by modulating ΔNp73. BMC Cancer. 2010 Jun 11;10. 282. https://doi.org/10.1186/1471-2407-10-282
Thangasamy, Thilakavathy ; Sittadjody, Sivanandane ; Mitchell, Geoffrey C. ; Mendoza, Erin E. ; Radhakrishnan, Vijayababu M. ; Limesand, Kirsten ; Burd, Randy M. / Quercetin abrogates chemoresistance in melanoma cells by modulating ΔNp73. In: BMC Cancer. 2010 ; Vol. 10.
@article{717513cb7fdd4185826fc5f245288db9,
title = "Quercetin abrogates chemoresistance in melanoma cells by modulating ΔNp73",
abstract = "Background: The alkylating agent Dacarbazine (DTIC) has been used in the treatment of melanoma for decades, but when used as a monotherapy for cancer only moderate response rates are achieved. Recently, the clinical use of Temozolomide (TMZ) has become the more commonly used analog of DTIC-related oral agents because of its greater bioavailability and ability to cross the blood brain barrier. The response rates achieved by TMZ are also unsatisfactory, so there is great interest in identifying compounds that could be used in combination therapy. We have previously demonstrated that the bioflavonoid quercetin (Qct) promoted a p53-mediated response and sensitized melanoma to DTIC. Here we demonstrate that Qct also sensitizes cells to TMZ and propose a mechanism that involves the modulation of a truncated p53 family member, ΔNp73.Methods: DB-1 melanoma (p53 wildtype), and SK Mel 28 (p53 mutant) cell lines were treated with TMZ (400 μM) for 48 hrs followed by Qct (75 μM) for 24 hrs. Cell death was determined by Annexin V-FITC staining and immunocytochemical analysis was carried out to determine protein translocation.Results: After treatment with TMZ, DB-1 cells demonstrated increased phosphorylation of Ataxia telangiectasia mutated (ATM) and p53. However, the cells were resistant to TMZ-induced apoptosis and the resistance was associated with an increase in nuclear localization of ΔNp73. Qct treatment in combination with TMZ abolished drug insensitivity and caused a more than additive induction of apoptosis compared to either treatment alone. Treatment with Qct, caused redistribution of ΔNp73 into the cytoplasm and nucleus, which has been associated with increased p53 transcriptional activity. Knockdown of ΔNp73 restored PARP cleavage in the TMZ treated cells, confirming its anti-apoptotic role. The response to treatment was predominantly p53 mediated as the p53 mutant SK Mel 28 cells showed no significant enhancement of apoptosis.Conclusion: This study demonstrates that Qct can sensitize cells to TMZ and that the mechanisms of sensitization involve modulation of p53 family members.",
author = "Thilakavathy Thangasamy and Sivanandane Sittadjody and Mitchell, {Geoffrey C.} and Mendoza, {Erin E.} and Radhakrishnan, {Vijayababu M.} and Kirsten Limesand and Burd, {Randy M}",
year = "2010",
month = "6",
day = "11",
doi = "10.1186/1471-2407-10-282",
language = "English (US)",
volume = "10",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Quercetin abrogates chemoresistance in melanoma cells by modulating ΔNp73

AU - Thangasamy, Thilakavathy

AU - Sittadjody, Sivanandane

AU - Mitchell, Geoffrey C.

AU - Mendoza, Erin E.

AU - Radhakrishnan, Vijayababu M.

AU - Limesand, Kirsten

AU - Burd, Randy M

PY - 2010/6/11

Y1 - 2010/6/11

N2 - Background: The alkylating agent Dacarbazine (DTIC) has been used in the treatment of melanoma for decades, but when used as a monotherapy for cancer only moderate response rates are achieved. Recently, the clinical use of Temozolomide (TMZ) has become the more commonly used analog of DTIC-related oral agents because of its greater bioavailability and ability to cross the blood brain barrier. The response rates achieved by TMZ are also unsatisfactory, so there is great interest in identifying compounds that could be used in combination therapy. We have previously demonstrated that the bioflavonoid quercetin (Qct) promoted a p53-mediated response and sensitized melanoma to DTIC. Here we demonstrate that Qct also sensitizes cells to TMZ and propose a mechanism that involves the modulation of a truncated p53 family member, ΔNp73.Methods: DB-1 melanoma (p53 wildtype), and SK Mel 28 (p53 mutant) cell lines were treated with TMZ (400 μM) for 48 hrs followed by Qct (75 μM) for 24 hrs. Cell death was determined by Annexin V-FITC staining and immunocytochemical analysis was carried out to determine protein translocation.Results: After treatment with TMZ, DB-1 cells demonstrated increased phosphorylation of Ataxia telangiectasia mutated (ATM) and p53. However, the cells were resistant to TMZ-induced apoptosis and the resistance was associated with an increase in nuclear localization of ΔNp73. Qct treatment in combination with TMZ abolished drug insensitivity and caused a more than additive induction of apoptosis compared to either treatment alone. Treatment with Qct, caused redistribution of ΔNp73 into the cytoplasm and nucleus, which has been associated with increased p53 transcriptional activity. Knockdown of ΔNp73 restored PARP cleavage in the TMZ treated cells, confirming its anti-apoptotic role. The response to treatment was predominantly p53 mediated as the p53 mutant SK Mel 28 cells showed no significant enhancement of apoptosis.Conclusion: This study demonstrates that Qct can sensitize cells to TMZ and that the mechanisms of sensitization involve modulation of p53 family members.

AB - Background: The alkylating agent Dacarbazine (DTIC) has been used in the treatment of melanoma for decades, but when used as a monotherapy for cancer only moderate response rates are achieved. Recently, the clinical use of Temozolomide (TMZ) has become the more commonly used analog of DTIC-related oral agents because of its greater bioavailability and ability to cross the blood brain barrier. The response rates achieved by TMZ are also unsatisfactory, so there is great interest in identifying compounds that could be used in combination therapy. We have previously demonstrated that the bioflavonoid quercetin (Qct) promoted a p53-mediated response and sensitized melanoma to DTIC. Here we demonstrate that Qct also sensitizes cells to TMZ and propose a mechanism that involves the modulation of a truncated p53 family member, ΔNp73.Methods: DB-1 melanoma (p53 wildtype), and SK Mel 28 (p53 mutant) cell lines were treated with TMZ (400 μM) for 48 hrs followed by Qct (75 μM) for 24 hrs. Cell death was determined by Annexin V-FITC staining and immunocytochemical analysis was carried out to determine protein translocation.Results: After treatment with TMZ, DB-1 cells demonstrated increased phosphorylation of Ataxia telangiectasia mutated (ATM) and p53. However, the cells were resistant to TMZ-induced apoptosis and the resistance was associated with an increase in nuclear localization of ΔNp73. Qct treatment in combination with TMZ abolished drug insensitivity and caused a more than additive induction of apoptosis compared to either treatment alone. Treatment with Qct, caused redistribution of ΔNp73 into the cytoplasm and nucleus, which has been associated with increased p53 transcriptional activity. Knockdown of ΔNp73 restored PARP cleavage in the TMZ treated cells, confirming its anti-apoptotic role. The response to treatment was predominantly p53 mediated as the p53 mutant SK Mel 28 cells showed no significant enhancement of apoptosis.Conclusion: This study demonstrates that Qct can sensitize cells to TMZ and that the mechanisms of sensitization involve modulation of p53 family members.

UR - http://www.scopus.com/inward/record.url?scp=77953296031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953296031&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-10-282

DO - 10.1186/1471-2407-10-282

M3 - Article

C2 - 20540768

AN - SCOPUS:77953296031

VL - 10

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

M1 - 282

ER -